Editorial & Medical Review Policy
Last Updated: March 1, 2026
At GLP-1.health, we are committed to producing the highest quality, evidence-based health content. This policy describes our editorial standards, medical review process, and how we handle corrections and updates.
Our Editorial Mission
GLP-1.health publishes independent, clinically accurate, and patient-centered information about GLP-1 receptor agonist medications and metabolic health. Our mission is to bridge the gap between complex pharmacological research and actionable patient education — enabling informed conversations between patients and their physicians. We do not publish content designed to sell specific products, mislead patients, or misrepresent the scientific evidence.
Content Development Process
All articles on GLP-1.health follow a structured development process: (1) Topic selection is based on patient search intent, clinical relevance, and gaps in existing patient education resources. (2) Initial drafts are prepared by health writers with expertise in medical writing and metabolic medicine. (3) All clinical claims, drug efficacy data, and prescribing information are sourced from FDA prescribing information, peer-reviewed journal articles (PubMed), clinical trial registries (ClinicalTrials.gov), and established medical guidelines. (4) Drafts are reviewed and approved by a board-certified physician on our Medical Review Board before publication.
Medical Review Standards
Our Medical Review Board consists of board-certified physicians who actively practice in endocrinology, internal medicine, and obesity medicine. Reviewers verify: accuracy of all clinical claims against current evidence; appropriate representation of statistical uncertainty and study limitations; absence of misleading or exaggerated claims about drug efficacy; inclusion of appropriate safety warnings and contraindications; compliance with FDA guidelines and current standard of care.
Sources & Evidence Standards
We prioritize the following evidence hierarchy: Level 1 — Randomized controlled trials published in peer-reviewed journals (NEJM, JAMA, Lancet, Diabetes Care); FDA official prescribing information and Drug Safety Communications; published systematic reviews and meta-analyses. Level 2 — Cohort studies, registry data, and real-world evidence. Level 3 — Expert consensus guidelines from AACE, ADA, TOS, and Obesity Medicine Association. We do not cite press releases or unreviewed preprints as primary evidence.
Corrections & Updates
We update our content when: new clinical trial data becomes available; FDA approvals, label updates, or safety communications are issued; pricing or availability information changes; errors are identified by our team or readers. Significant corrections are noted at the article level with the correction date. Content is reviewed at minimum on a quarterly basis by our medical team for ongoing accuracy.
Independence from Advertising & Affiliates
Our editorial content is developed and reviewed independently of our commercial partnerships. Affiliate arrangements and sponsorships never influence article topics, clinical conclusions, or drug recommendations. Our medical reviewers receive no compensation tied to product promotion or click-through rates. Drug rankings, comparisons, and clinical assessments reflect the evidence, not commercial relationships.
Conflict of Interest Policy
All Medical Review Board members disclose any actual or potential conflicts of interest prior to reviewing content. Members who have received speaking honoraria, consulting fees, or research funding from manufacturers of GLP-1 medications within the past 24 months do not serve as primary reviewers for articles directly comparing those drugs. All disclosures are available on our physician profile pages.
Contact Our Editorial Team
To submit a correction, request a clarification, or report a factual error, please contact: editorial@glp1.health. We respond to all editorial inquiries within 5 business days. For medical emergencies, contact your physician or call 911.